"The Champagne should probably be kept on ice, at least until the two presidents put pen to paper," said state-owned media China Daily.Traderead more
U.S. stock index futures turned lower after China said it needed to have further discussions before it would sign off on the so-called phase one trade deal President Trump...US Marketsread more
Analysts say the partial U.S.-China trade deal doesn't touch on thorny issues plaguing both sides, and warn talks could break down again.World Economyread more
Economists polled by Reuters had expected Chinese exports denominated in the U.S. dollar to fall by 3% and imports to decline by 5.2% in September, compared to a year ago.China Economyread more
Boeing's board removed CEO Dennis Muilenburg as chairman amid the fall out of two 737 Max crashes that killed 346 people.Aerospace & Defenseread more
The U.K. and EU are gearing up for what could be the busiest week in British politics since June 2016.Europe Politicsread more
The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
"It seems like what the two leaders have done is try to set some of the thorny political issues to the side," said Dhruva Jaishankar, director of the U.S. Initiative at the...Asia Politicsread more
Beijing will be opening up its financial industry to foreign ownership from January, namely in the areas of futures, mutual funds and securities.China Economyread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
The prescription drugs that have seen the most rapid growth in cost in the U.S. don't treat depression, cholesterol or even autoimmune diseases.
Blockbuster male libido treatments Viagra and Cialis saw the biggest price hikes among the 17 top-selling brand-name drugs that have seen costs surges from 2012 through 2017, according to a new study published Friday in the peer-reviewed Journal of the American Medical Association.
Researchers from the Scripps Research Translational Institute analyzed six years of pharmacy claims data from the Blue Cross Blue Shield Axis, a database of more than 35 million individuals with private prescription drug insurance. They found there was a "near universal" increase in net prices of 49 brand-name drugs with 17 of those drugs seeing prices double over the time period.
The largest price increase came from Pfizer's Viagra, which surged by 190% over the six-year time period to $370 from $127 per prescription, according to the study. That was followed by Viagra rival Cialis, produced by Eli Lily, which rose by 187% to $365 from $127 for a prescription. Eli Lilly's osteoporosis drug Forteo came in third with a 177% price increase.
Nathan Wineinger, an assistant professor at Scripps Research and lead author of the study, said researchers didn't see any difference in cost increases between drugs that had been on the market for a significant period of time, were relatively new or a had a generic version. That "was disheartening," he said.
Researchers said they were were limited by a lack of information on drug price rebates and how they affected net prices. Additionally, researchers only examined drugs that have exceeded $500 million in U.S. sales or $1 billion in sales worldwide.
The study was funded with a grant from the National Institutes of Health National Center for Advancing Translational Sciences. Wineinger said Blue Cross Blue Shield had no influence over the study.
High drug costs have become a rare bipartisan issue in Washington with lawmakers on both sides of the aisle demanding something be done. President Donald Trump has made lowering prices one of the key issues of his administration. Democrats are jockeying to prove they can lead reform.
Earlier this month, the Trump administration announced pharmaceutical companies would be required to disclose the list price of their prescription medicines in television commercials as soon as this summer. Health and Human Services Secretary Alex Azar told CNBC that the administration hopes the cost disclosures will eventually shame drugmakers into lowering their prices.
Drugmakers have been resistant to advertising list prices, the price before rebates and discounts, saying it's simply the price that's advertised, and not what consumers actually pay.
Pharma executives have instead thrown their support behind a Trump administration proposal that would give consumers an estimated $29 billion in rebates now paid to pharmacy benefit managers. Drug manufacturers pay PBMs the rebates for getting their drugs covered by Medicare's Part D prescription plan.
The drugmakers weren't immediately available for comment.